1
Keiji Iwasaki, Yuji Iwashita, Taketoshi Okami: Hemoglobin combined with a poly(alkylene oxide). Ajinomoto Co, Oblon Fisher Spivak McClelland & Maier, June 2, 1987: US04670417 (544 worldwide citation)

There is disclosed hemoglobin modified in that a poly(alkylene oxide) is bonded thereto by a bond between a terminal group of said poly(alkylene oxide) and an amino group of said hemoglobin, said bond having the structure:


2
Martin James MacPhee, William Nash Drohan, Carlos I Lasa Jr, Gene Liau, Christian Haudenschild: Supplemented and unsupplemented tissue sealants, methods of their production and use. The American National Red Cross, Sterne Kessler Goldstein & Fox P L L C, March 6, 2001: US06197325 (248 worldwide citation)

This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, a ...


3
Edward A Boyse, Hal E Broxmeyer, Gordon W Douglas: Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood. Biocyte Corporation, Pennie & Edmonds, April 2, 1991: US05004681 (199 worldwide citation)

The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for ...


4
Edward A Boyse, Hal E Broxmeyer, Gordon W Douglas: Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use. Biocyte Corporation, March 9, 1993: US05192553 (196 worldwide citation)

The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for ...


5
Daniel J Capon, Arthur Weiss, Brian A Irving, Margo R Roberts, Krisztina Zsebo: Chimeric chains for receptor-associated signal transduction pathways. Cell Genesys, The Regents of the University of California, Bertram I Rowland, October 25, 1994: US05359046 (195 worldwide citation)

Chimeric proteins and DNA sequence encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathwa ...


6
Michael Stroetmann: Fibrinogen-containing dry preparation, manufacture and use thereof. Serapharm Michael Stroetmann, Gordon W Hueschen, April 17, 1984: US04442655 (182 worldwide citation)

A dry preparation having a foam-like and, respectively, fleece-like structure obtained by freeze-drying consists, apart from thrombin in at least catalytically active amounts, substantially of approx. 10 to 95% by weight of fibrin and approx. 5 to 90% by weight of fibrinogen. For the preparation the ...


7
Otto Schwarz, Yendra Linnau, Franz Loblich, Thomas Seelich: Tissue adhesive. Immuno Aktiengesellschaft fur Chemisch Medizinische Produkte, Brumbaugh Graves Donohue & Raymond, March 22, 1983: US04377572 (170 worldwide citation)

This invention relates to a tissue adhesive used in mammals for among other things to connect tissue or organs, in sealing wounds, stopping bleeding and healing wounds. The adhesive comprises specified amounts of factor XIII, fibrinogen, cold-insoluble globulin and albumin and plasminogen-activator ...


8
Avner Yayon, Rachel Glicklis: Plasma protein matrices and methods for their preparation. ProChon Biotech, Winston & Strawn, March 7, 2006: US07009039 (167 worldwide citation)

A freeze dried biocompatible matrix comprising plasma proteins, useful as implants for tissue engineering as well as in biotechnology, and methods of producing the matrix are provided. Mechanical and physical parameters can be controlled by use of auxiliary components or additives which may be remov ...


9

10
Michael Stroetmann: Enriched plasma derivative for advancement of wound closure and healing. Serapharm Michael Stroetmann, Gordon W Hueschen, January 24, 1984: US04427650 (148 worldwide citation)

A preparation for accelerated hemostasis and optimized biochemical control of wound closure ("tissue adhesive") consists only of solid, powdery, biologically active constituents and contains 60 to 96% by weight of fibrinogen, which is largely liberated from cryo-insoluble globulin, 0.05 to 5% by wei ...